Navigation Links
LigoCyte Pharmaceuticals Finalizes Agreement for $28M Series 'C' Financing Round
Date:3/18/2008

BOZEMAN, Mont., March 18 /PRNewswire/ -- LigoCyte Pharmaceuticals, Inc., a vaccine company in Bozeman, Montana, announced that the company has successfully finalized an agreement for a $28 million venture capital financing round to further clinical development of its two lead vaccines against norovirus and influenza.

The private equity investment is being led by Forward Ventures, JAFCO, and Novartis Venture Fund with significant participation from Fidelity Biosciences and MedImmune Ventures. Additional investors include Athenian Venture Partners and MC Life Sciences Ventures (Mitsubishi International Corporation). Seaview Securities serves as the placement agent for the transaction.

LigoCyte, which develops products based on its virus-like particle (VLP) and monoclonal antibody technologies, has focused efforts on vaccines for important gastrointestinal and respiratory markets. Recent advances by the company of its VLP vaccines for norovirus and influenza propelled the current investment. In particular, the company is currently completing a Phase I clinical study of the norovirus vaccine and plans to commence a live-virus challenge study in human volunteers.

Norovirus is the leading cause of infectious gastroenteritis in the United States and other developed countries. Norovirus outbreaks are becoming increasingly recognized as an important contributor to morbidity and mortality in vulnerable populations, particularly in pediatric and geriatric subjects. Recent progress in detection and surveillance has increased awareness of norovirus in the health care community, and epidemic outbreaks in hospitals, nursing homes and schools highlight the significance of the medical need for a safe and effective vaccine.

In addition to the norovirus vaccine program, LigoCyte has developed an influenza VLP vaccine that has demonstrated significant cross-protection against lethal influenza challenge in the industry standard model of vaccine perform
'/>"/>

SOURCE LigoCyte Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
2. Vion Pharmaceuticals to Host Conference Call to Discuss 2007 Fourth Quarter and Year-End Financial Results
3. MiddleBrook Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
4. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
5. NPS Pharmaceuticals Reports 2007 Financial Results
6. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
7. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
8. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
9. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
10. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
11. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  Prima Biomed Ltd. ... that is striving to become a leader in the ... recently announced that the final CVac data from the ... a clear trend for a clinically meaningful improvement in ... second remission patients. In the group of ...
(Date:5/21/2015)... Imagine being able to probe and truly ... Being able to read faces and enjoy genuine invisible ... their thoughts and actions like never before. Use ... unique abstract paintings and video, or, play a completely ... as it creates action, dialog, and outcomes based on ...
(Date:5/21/2015)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced positive updated results from its ongoing ... treatment of unresectable glioblastoma multiforme (GBM), a deadly ... is designed to investigate the preliminary efficacy and ... progressed following prior treatment with surgery, radiation and ...
(Date:5/21/2015)... - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: ... on the development of autologous cell therapies, announced ... Society for Cellular Therapy (ISCT) on RepliCel,s autologous ... a Phase 1/2 clinical trial.  The presentation, taking ... PM to 7:00 PM local time, will review ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
... Va., June 27, 2011 A Continuing Medical Education (CME) ... of key risk factors , will be hosted at the ... 2011 from 8:30am to 1pm. "Beating ... Education credits, is designed to help doctors eradicate this disease ...
... JUPITER, Fla., June 27, 2011 Dyadic International, ... company focused on the discovery, development, manufacture and ... industrial enzyme, bioenergy, and biopharmaceutical industries, announced today ... development and license agreement with a key provider ...
... PharmacoFore, Inc., a privately held biopharmaceutical company developing ... Dr. Joseph Stauffer as Chief Medical Officer & VP, ... Property. Dr. Joseph Stauffer ... Prior to joining PharmacoFore, Dr. Stauffer ...
Cached Biology Technology:Health Diagnostic Laboratory Inc. Sponsors Lecture Series in West Palm Beach, Florida 2Dyadic International Enters Into Research and License Agreement With Major Player in the Animal Feed Industry 2Dyadic International Enters Into Research and License Agreement With Major Player in the Animal Feed Industry 3PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property 2PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property 3PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property 4
(Date:5/19/2015)... , May 19, 2015  Technology is rapidly ... internally and in the cloud. Passwords and their management ... of OTP and standards-based specifications such as those developed ... outmoded use of passwords presents for BYOD, COPE, IoT, ... unified biometric identity protocol. In response ...
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
(Date:5/11/2015)...  Through a well-rounded UAS delegation representing private industry, government, ... showing at AUVSI,s Unmanned 2015 conference last week in ... UAS industry met with over 200 hundred people ... the UAS ecosystem. "Our message is clear ... Aerospace Rich Knoll . "If you want to fly ...
Breaking Biology News(10 mins):HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... the University of Houston for a two-day conference to discuss ... , The UH Texas Obesity Research Center (TORC) ... UH M.D. Anderson Library, Rockwell Pavilion. , "We ... that others will see the wealth of obesity research that ...
... hopeful moms-to-be learn, there are important considerations to the ... environment, regular hormonal injections and the timing of the ... procedure. Now a Tel Aviv University researcher ... look at the role that gravity and other biomechanical ...
... team of scientists led by the UK has been given ... frontiers - an ancient lake hidden deep beneath Antarctica,s ice ... the size of Lake Windermere (UK) may have been ... unique forms of life. The team hopes the exploration will ...
Cached Biology News:Texas Obesity Research Center at UH assembles researchers to discuss obesity 2Engineering bouncing babies, 1 at a time 2Final frontier: Mission to explore buried ancient Antarctic lake given green light 2
... The European Collection of Cell Cultures (ECACC) ... West of the West of England, Bristol, ... the quality control of HER2, oestrogen and ... paraffin wax sections of formalin fixed, breast ...
... Electro-4 design allows "4 gels in one ... possible to run 200,samples or more in ... to four,horizontal gels. To ensure even migration, ... number of gels being run. Ideal for,high ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
... several isoprostanes produced from arachidonic acid during lipid ... the rat. 8-iso PGE2 inhibits U-46619 or I-BOP-induced ... 5 µM, respectively. When infused into the renal ... 4 mg/kg/min, 8-iso PGE2 decreases the GFR and ...
Biology Products: